Compare Stocks: ALVR, ESLA, ACET, and QNCX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$3.20 -6.4%	$7.03	$3.18 ▼ $12.32	$35.67M	1.62	202,391 shs	250,229 shs
ALVR AlloVir	$2.03 -4.7%	$2.95	$7.96 ▼ $24.15	$10.24M	0.63	15,685 shs	60,195 shs
ESLA Estrella Immunopharma	$0.43 -33.3%	$0.58	$0.24 ▼ $3.15	$35.74M	0.93	5.60 million shs	616,973 shs
QNCX Quince Therapeutics	$31.73	$30.71	$15.10 ▼ $909.98	$32.27M	1.33	31,090 shs	N/A

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	-6.43%	-18.78%	-50.77%	-65.26%	-73.33%
ALVR AlloVir	0.00%	+8.56%	-24.81%	-49.88%	-59.64%
ESLA Estrella Immunopharma	-33.32%	-53.66%	-8.91%	-39.45%	-82.38%
QNCX Quince Therapeutics	0.00%	0.00%	+8.66%	+15.76%	-90.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$3.20 -6.4%	$7.03	$3.18 ▼ $12.32	$35.67M	1.62	202,391 shs	250,229 shs
ALVR AlloVir	$2.03 -4.7%	$2.95	$7.96 ▼ $24.15	$10.24M	0.63	15,685 shs	60,195 shs
ESLA Estrella Immunopharma	$0.43 -33.3%	$0.58	$0.24 ▼ $3.15	$35.74M	0.93	5.60 million shs	616,973 shs
QNCX Quince Therapeutics	$31.73	$30.71	$15.10 ▼ $909.98	$32.27M	1.33	31,090 shs	N/A

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	-6.43%	-18.78%	-50.77%	-65.26%	-73.33%
ALVR AlloVir	0.00%	+8.56%	-24.81%	-49.88%	-59.64%
ESLA Estrella Immunopharma	-33.32%	-53.66%	-8.91%	-39.45%	-82.38%
QNCX Quince Therapeutics	0.00%	0.00%	+8.66%	+15.76%	-90.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACET Adicet Bio	2.89	Moderate Buy	$37.80	1,081.25% Upside
ALVR AlloVir	0.00	N/A	N/A	N/A
ESLA Estrella Immunopharma	2.00	Hold	$8.00	1,776.61% Upside
QNCX Quince Therapeutics	2.64	Moderate Buy	$189.88	498.41% Upside

Current Analyst Ratings Breakdown

Latest ALVR, ESLA, ACET, and QNCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/28/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/13/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/9/2026	QNCX Quince Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$72.00
10/1/2026	QNCX Quince Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
9/29/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/29/2026	ACET Adicet Bio	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/29/2026	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/28/2026	ACET Adicet Bio	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$25.00 ➝ $28.00
9/28/2026	ACET Adicet Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$27.00 ➝ $34.00
9/24/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/24/2026	QNCX Quince Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$70.00

(Data available from 11/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACET Adicet Bio	N/A	N/A	N/A	N/A	$16.62 per share	N/A
ALVR AlloVir	N/A	N/A	N/A	N/A	$29.35 per share	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	($0.27) per share	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACET Adicet Bio	-$116.80M	-$11.45	N/A	N/A	N/A	N/A	-74.90%	-60.87%	11/4/2026 (Estimated)
ALVR AlloVir	-$190.42M	-$20.23	N/A	N/A	N/A	N/A	-71.03%	-61.27%	N/A
ESLA Estrella Immunopharma	-$13.06M	-$0.24	N/A	N/A	N/A	N/A	N/A	-328.72%	12/2/2026 (Estimated)
QNCX Quince Therapeutics	-$83.98M	-$156.71	N/A	N/A	N/A	N/A	N/A	-133.84%	11/11/2026 (Estimated)

Latest ALVR, ESLA, ACET, and QNCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	QNCX Quince Therapeutics	-$1.3850	N/A	N/A	N/A	N/A	N/A
11/4/2026	Q3 2026	ACET Adicet Bio	-$1.56	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	-$12.31	+$15.71	-$12.31	N/A	N/A
8/13/2026	Q2 2026	ESLA Estrella Immunopharma	-$0.09	-$0.05	+$0.04	-$0.05	N/A	N/A
8/5/2026	Q2 2026	ACET Adicet Bio	-$1.69	-$1.99	-$0.30	-$1.99	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACET Adicet Bio	N/A	N/A	N/A	N/A	N/A
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACET Adicet Bio	0.01	6.71	6.71
ALVR AlloVir	N/A	86.78	86.78
ESLA Estrella Immunopharma	N/A	0.20	0.20
QNCX Quince Therapeutics	N/A	14.52	14.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACET Adicet Bio	83.89%
ALVR AlloVir	66.05%
ESLA Estrella Immunopharma	0.35%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
ACET Adicet Bio	3.40%
ALVR AlloVir	32.07%
ESLA Estrella Immunopharma	5.80%
QNCX Quince Therapeutics	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACET Adicet Bio	102	9.36 million	9.04 million	Optionable
ALVR AlloVir	110	5.04 million	3.43 million	No Data
ESLA Estrella Immunopharma	3	43.50 million	40.98 million	Not Optionable
QNCX Quince Therapeutics	60	1.02 million	960,000	No Data

ALVR, ESLA, ACET, and QNCX Headlines

Recent News About These Companies

IRulya Therapeutics stock sharpens focus on LAM-001 pipeline

October 29, 2026 | ad-hoc-news.deA

Quince Therapeutics Appoints Brigette Roberts, M.D. as CEO Amid Executive Changes and Rebranding

October 11, 2026 | kalkinemedia.comK

Quince Therapeutics Renames as IRulya Therapeutics, Advances Pulmonary Drug Development

October 9, 2026 | finance.yahoo.com

Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

October 9, 2026 | globenewswire.com

Quince Therapeutics stock wins approval for major share issuance

October 7, 2026 | ad-hoc-news.deA

Quince Shareholders Approve New Equity and Stock Plans

October 6, 2026 | tipranks.com

Leerink Partners Reaffirms Their Buy Rating on Quince Therapeutics (QNCX)

October 1, 2026 | theglobeandmail.com

Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript

September 28, 2026 | seekingalpha.com

Rodman & Renshaw initiates coverage of Quince Therapeutics with a buy

September 24, 2026 | msn.com

Quince Therapeutics stock falls 3.83 percent on Nasdaq

September 24, 2026 | ad-hoc-news.deA

Quince Therapeutics stock prepares for LAM-001 KOL event as shares trade below recent highs

September 19, 2026 | ad-hoc-news.deA

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on ...

September 17, 2026 | finance.yahoo.com

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

September 17, 2026 | globenewswire.com

Quince Therapeutics to Participate in September 2026 Investor Conferences

September 3, 2026 | quiverquant.comQ

Quince Therapeutics to Participate in September 2026 Investor Conferences

September 3, 2026 | globenewswire.com

Quince Therapeutics Announces Planned Presidential Leadership Transition

August 27, 2026 | tipranks.com

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

August 14, 2026 | globenewswire.com

Quince Therapeutics

July 6, 2026 | fool.com

Quince Therapeutics Stock Short Interest Report | NASDAQ:QNCX | Benzinga

July 2, 2026 | benzinga.com

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

June 30, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALVR, ESLA, ACET, and QNCX Company Descriptions

Adicet Bio NASDAQ:ACET

$3.20 -0.22 (-6.43%)

Closing price 11/2/2026 04:00 PM Eastern

Extended Trading

$3.76 +0.56 (+17.50%)

As of 07:52 AM Eastern

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

AlloVir NASDAQ:ALVR

$2.03 -0.10 (-4.69%)

As of 10/30/2026

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Estrella Immunopharma NASDAQ:ESLA

$0.43 -0.21 (-33.32%)

Closing price 11/2/2026 04:00 PM Eastern

Extended Trading

$0.44 +0.01 (+2.98%)

As of 07:21 AM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Quince Therapeutics NASDAQ:QNCX

$31.73 0.00 (0.00%)

As of 10/13/2026

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALVR, ESLA, ACET, and QNCX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALVR, ESLA, ACET, and QNCX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALVR, ESLA, ACET, and QNCX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALVR, ESLA, ACET, and QNCX Company Descriptions

Adicet Bio NASDAQ:ACET

AlloVir NASDAQ:ALVR

Estrella Immunopharma NASDAQ:ESLA

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALVR, ESLA, ACET, and QNCX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALVR, ESLA, ACET, and QNCX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALVR, ESLA, ACET, and QNCX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALVR, ESLA, ACET, and QNCX Company Descriptions

Adicet Bio NASDAQ:ACET

AlloVir NASDAQ:ALVR

Estrella Immunopharma NASDAQ:ESLA

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools